Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Biological Psychiatry

• Publication date

  2014-03-01

• Fields of study

  Biology, Medicine, Psychology

• Identifiers
  DOI 10.1016/j.biopsych.2013.06.011PMID 23890739
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis: findings in a second cohort.

  2013cited by this paper
• Anterior Cingulate Glutamate Levels Related to Clinical Status Following Treatment in First-Episode Schizophrenia

  2012cited by this paper
• Dopamine synthesis capacity in patients with treatment-resistant schizophrenia.

  2012cited by this paper
• The nature of dopamine dysfunction in schizophrenia and what this means for treatment.

  2012cited by this paper
• Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study

  2011cited by this paper
• Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study.

  2011cited by this paper
• Review: The biological basis of antipsychotic response in schizophrenia

  2010cited by this paper
• Field strength dependence of PRESS timings for simultaneous detection of glutamate and glutamine from 1.5 to 7T.

  2010cited by this paper
• Regional dopamine synthesis in patients with schizophrenia using L-[beta-11C]DOPA PET.

  2009cited by this paper
• Elevated striatal dopamine function linked to prodromal signs of schizophrenia.

  2009cited by this paper
• Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume.

  2009cited by this paper
• Elevated [18F]Fluorodopamine Turnover in Brain of Patients with Schizophrenia: An [18F]Fluorodopa/Positron Emission Tomography Study

  2007cited by this paper
• Remission in schizophrenia: proposed criteria and rationale for consensus.

  2005cited by this paper
• Treatment Refractory Schizophrenia

  2004cited by this paper
• Glutamate as a therapeutic target in psychiatric disorders

  2004cited by this paper
• Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F]fluorodopa study.

  2004cited by this paper
• Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia

  2002cited by this paper
• Polydiagnostic approaches to measuring and classifying psychopathology.

  2001cited by this paper
• Management of treatment resistance in schizophrenia.

  2001cited by this paper
• Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET.

  1999cited by this paper
• Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia.

  1999cited by this paper
• Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients.

  1995cited by this paper
• Elevated dopa decarboxylase activity in living brain of patients with psychosis.

  1994cited by this paper
• Estimation of metabolite concentrations from localized in vivo proton NMR spectra

  1993cited by this paper

• Adjunctive treatment with evenamide, a glutamate modulator, is associated with clinically meaningful benefits in patients with treatment-resistant schizophrenia and inadequate response to antipsychotics: recent clinical findings from randomized trials

  2026cites this paper
• Frontotemporal cortical thinning and insular surface area reduction in schizophrenia with predominant negative symptoms.

  2026cites this paper
• [Biological aspects of drug resistance in schizophrenia].

  2026cites this paper
• Treatment-resistant schizophrenia: pathophysiology and the role of neuroimaging and therapeutics

  2026cites this paper
• Elevated glutamine but not glutamate is associated with clozapine eligibility in an early psychosis sample

  2026cites this paper
• Declines and pronounced state-level variation in clozapine use among Medicare patients

  2025cites this paper
• Why is Clozapine uniquely Effective in Treatment Resistant Schizophrenia?

  2025cites this paper
• Activity-dependent modulation of glutamate, glutamine and glutathione in first-episode schizophrenia: A 7T functional MRS study.

  2025cites this paper
• Cerebral glutamate levels over two years in initially antipsychotic-naïve first-episode patients with psychosis are related to clinical symptoms and cognition

  2025cites this paper
• Glutamate-Based Therapeutic Strategies for Schizophrenia: Emerging Approaches Beyond Dopamine

  2025cites this paper
• Association of astrocyte-specific gene expression in the dorsolateral prefrontal cortex with clozapine treatment in schizophrenia

  2025cites this paper
• In vivo assessment of GABAergic inhibition and glutamate facilitation in treatment-resistant schizophrenia: a TMS study integrating clinical, cognitive, and neurophysiological evaluations

  2025cites this paper
• Resolving the heterogeneity of dopamine subsystems dysfunction in schizophrenia: a PET meta-analysis

  2025cites this paper
• Investigating DRD2 and HTR2A polymorphisms in treatment-resistant schizophrenia: a comparative analysis with other treatment-resistant mental disorders and the healthy state.

  2025cites this paper
• Advancing Understanding of Treatment Response in Schizophrenia With Psychosis Using a Novel Dynamic Reward Task.

  2025cites this paper
• Associations of neuromelanin in the substantia nigra with antipsychotic response in schizophrenia

  2025cites this paper
• EVENAMIDE AS ADD-ON TREATMENT FOR PATIENTS WITH CHRONIC SCHIZOPHRENIA NOT RESPONDING ADEQUATELY TO THEIR CURRENT ANTIPSYCHOTIC MEDICATION: RESULTS OF A POTENTIALLY PIVOTAL, PHASE II/III, INTERNATIONAL, RANDOMIZED, DOUBLE BLIND, PLACEBO- CONTROLLED TRIAL

  2025cites this paper
• Evenamide reverses schizophrenia-related dysfunction in a neurodevelopmental animal model

  2025cites this paper
• Molecular Underpinning of Treatment-Resistant Schizophrenia: A Putative Different Neurobiology from Treatment-Responsive Schizophrenia

  2025cites this paper
• REMARKABLE EFFICACY OF EVENAMIDE, A GLUTAMATE ANTAGONIST, AS AN ADD-ON TO ANTIPSYCHOTICS IN PATIENTS WITH TREATMENT RESISTANT SCHIZOPHRENIA (TRS): RESULTS FROM A ONE-YEAR, OPEN- LABEL, DOSE-COMPARATIVE, RANDOMIZED, TREATMENT TRIAL

  2025cites this paper
• Network analysis of clinical features in patients with treatment-resistant schizophrenia

  2025cites this paper
• Current perspectives on the recognition and management of treatment-resistant schizophrenia: challenges and opportunities

  2025cites this paper
• Radiomic Analysis of Striatal [18F]FDOPA PET Imaging in Patients with Psychosis for the Identification of Antipsychotic Response

  2025cites this paper
• Non-Clozapine interventions in treatment-resistant schizophrenia: a systematic review and meta-analysis

  2025cites this paper
• Machine learning-based prediction of antipsychotic efficacy from brain gray matter structure in drug-naive first-episode schizophrenia

  2025cites this paper
• Neuropharmacological targets for schizophrenia treatment: An update.

  2025cites this paper
• NMDA glutamate receptor antagonist MK‐801 induces proteome changes in adult human brain slices which are partially counteracted by haloperidol and clozapine

  2024cites this paper
• The mechanisms of persisting disability in schizophrenia: imprecise predictive coding via cortico-striatal-thalamo-cortical loop dysfunction.

  2024cites this paper
• Glutamate and GABA levels in the anterior cingulate cortex in treatment resistant first episode psychosis patients.

  2024cites this paper
• Association of SLC6A3 variants with treatment-resistant schizophrenia: a genetic association study of dopamine-related genes in schizophrenia

  2024cites this paper
• Dysfunction of the NMDA Receptor in the Pathophysiology of Schizophrenia and/or the Pathomechanisms of Treatment-Resistant Schizophrenia

  2024cites this paper
• Gene expression imputation provides clinical and biological insights into treatment-resistant schizophrenia polygenic risk.

  2024cites this paper
• Exploring causal mechanisms of psychosis risk

  2024cites this paper
• Functional Connectivity Biomarkers in Schizophrenia.

  2024cites this paper
• Neurocognition and NMDAR co-agonists pathways in individuals with treatment resistant first-episode psychosis: a 3-year follow-up longitudinal study

  2024cites this paper
• Overcoming the barriers to identifying and managing treatment-resistant schizophrenia and to improving access to clozapine: A narrative review and recommendation for clinical practice.

  2024cites this paper
• Therapeutic Effect of Evenamide, a Glutamate Inhibitor, in Patients With Treatment-Resistant Schizophrenia (TRS): Final, 1-Year Results From a Phase 2, Open-Label, Rater-Blinded, Randomized, International Clinical Trial

  2024cites this paper
• Glutamate, GABA and NAA in treatment-resistant schizophrenia: a systematic review of the effect of clozapine and group differences between clozapine-responders and non-responders.

  2024cites this paper
• CLEAR – clozapine in early psychosis: study protocol for a multi-centre, randomised controlled trial of clozapine vs other antipsychotics for young people with treatment resistant schizophrenia in real world settings

  2024cites this paper
• Splitting Schizophrenia: Divergent Cognitive and Educational Outcomes Revealed by Genomic Structural Equation Modelling.

  2024cites this paper
• Dimensional Neuroimaging Endophenotypes: Neurobiological Representations of Disease Heterogeneity Through Machine Learning.

  2024cites this paper
• A novel locomotion-based prepulse inhibition assay in zebrafish larvae

  2024cites this paper
• Does relapse cause illness progression in first-episode psychosis? A review.

  2024cites this paper
• Immunophenotyping schizophrenia subtypes stratified by antipsychotic response.

  2024cites this paper
• New drug treatments for schizophrenia: a review of approaches to target circuit dysfunction.

  2024cites this paper
• The importance of oxidative biomarkers in diagnosis, treatment, and monitoring schizophrenia patients.

  2024cites this paper
• Dimensional Neuroimaging Endophenotypes: Neurobiological Representations of Disease Heterogeneity Through Machine Learning

  2024influential citation
• Clozapine treatment and astrocyte activity in treatment resistant schizophrenia: A proton magnetic resonance spectroscopy study.

  2024cites this paper
• Deterioration in cognitive control related mPFC function underlying development of treatment resistance in early psychosis

  2024cites this paper
• Multiple serum anti-glutamate receptor antibody levels in clozapine-treated/naïve patients with treatment-resistant schizophrenia

  2024cites this paper
• Psychotic disorders as a framework for precision psychiatry

  2023cites this paper
• Does clozapine treat antipsychotic-induced behavioural supersensitivity through glutamate modulation within the striatum?

  2023cites this paper
• Role of the immune-kynurenine pathway in treatment-resistant schizophrenia.

  2023cites this paper
• Glutamatergic basis of antipsychotic response in first-episode psychosis: a dual voxel study of the anterior cingulate cortex

  2023cites this paper
• Treatment resistance NMDA receptor pathway polygenic score is associated with brain glutamate in schizophrenia

  2023cites this paper
• Genetic variation in glutamatergic genes moderates the effects of childhood adversity on brain volume and IQ in treatment-resistant schizophrenia

  2023cites this paper
• Greater Choline-Containing Compounds and Myo-inositol in Treatment-Resistant vs. Responsive Schizophrenia: A 1H-Magnetic Resonance Spectroscopy Meta-Analysis.

  2023cites this paper
• Meta-analytic evidence of elevated choline, reduced N-acetylaspartate, and normal creatine in schizophrenia and their moderation by measurement quality, echo time, and medication status

  2023cites this paper
• Metastability as a candidate neuromechanistic biomarker of schizophrenia pathology

  2023cites this paper
• Treatment-Resistant Schizophrenia, Clozapine Resistance, Genetic Associations, and Implications for Precision Psychiatry: A Scoping Review

  2023cites this paper
• Effects of low-dose combined olanzapine and sertraline on negative and depressive symptoms in treatment-resistant outpatients with acute exacerbated schizophrenia

  2023cites this paper
• Variability and magnitude of brain glutamate levels in schizophrenia: a meta and mega-analysis

  2023cites this paper
• Dopamine Dynamics and Neurobiology of Non-Response to Antipsychotics, Relevance for Treatment Resistant Schizophrenia: A Systematic Review and Critical Appraisal

  2023cites this paper
• Evidence for upregulation of excitatory synaptic transmission in the substantia nigra in Schizophrenia: a postmortem ultrastructural study

  2023cites this paper
• Cortical thinning in relation to impaired insight into illness in patients with treatment resistant schizophrenia

  2023cites this paper
• Negative symptoms in drug-naive patients with a first-episode psychosis (FEP).

  2023cites this paper
• Decrease in gamma-band auditory steady-state response in patients with treatment-resistant schizophrenia.

  2023cites this paper
• Polygenic risk scores for schizophrenia and treatment resistance: New data, systematic review and meta-analysis.

  2023cites this paper
• Music rhythm perception and production relate to treatment response in schizophrenia.

  2023cites this paper
• Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment

  2023cites this paper
• Clinical response to treatment with a partial dopamine agonist is related to changes in reward processing.

  2023cites this paper
• The phenomenon of therapeutic resistance in the treatment of schizophrenia: the possibilities of modern diagnostics and methods of anti-resistant effects

  2023cites this paper
• Altered functional connectivity in anterior cingulate cortex subregions in treatment-resistant schizophrenia patients.

  2023cites this paper
• Schizophrenia: One Name, Many Different Manifestations.

  2022cites this paper
• Peripheral biomarkers of treatment-resistant schizophrenia: Genetic, inflammation and stress perspectives

  2022cites this paper
• Decreased cortical gyrification and surface area in the left medial parietal cortex in patients with treatment‐resistant and ultratreatment‐resistant schizophrenia

  2022cites this paper
• Metastability as a neuromechanistic biomarker of schizophrenia pathology

  2022cites this paper
• Altered Patterns of Brain Glucose Metabolism Involve More Extensive and Discrete Cortical Areas in Treatment-resistant Schizophrenia Patients Compared to Responder Patients and Controls: Results From a Head-to-Head 2-[18F]-FDG-PET Study.

  2022cites this paper
• Update on novel antipsychotics and pharmacological strategies for treatment-resistant schizophrenia

  2022cites this paper
• A longitudinal investigation of GABA, glutamate, and glutamine across the insula during antipsychotic treatment of first-episode schizophrenia.

  2022cites this paper
• Impact of cannabis use and its cessation on the dosage and the efficacy of antipsychotic drugs in in- and outpatients with schizophrenia taking medication: A systematic review and meta-analysis.

  2022cites this paper
• Naturalistic study on the use of clozapine in the early phases of non-affective psychosis: A 10-year follow-up study in the PAFIP-10 cohort.

  2022cites this paper
• The effect of antipsychotics on glutamate levels in the anterior cingulate cortex and clinical response: A 1H-MRS study in first-episode psychosis patients

  2022cites this paper
• An Analytical Psychology Conceptualisation of Psychosis in Modern Psychiatry

  2022cites this paper
• Treatment-resistant schizophrenia: How far have we traveled?

  2022influential citation
• Comparison of Efficacy and Safety Between Low-Dose Ziprasidone in Combination With Sertraline and Ziprasidone Monotherapy for Treatment-Resistant Patients With Acute Exacerbation Schizophrenia: A Randomized Controlled Trial

  2022cites this paper
• Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment

  2022cites this paper
• Cognitive dysfunction in schizophrenia: An expert group paper on the current state of the art

  2022cites this paper
• Altered Neuroanatomical Signatures of Patients With Treatment-Resistant Schizophrenia Compared to Patients With Early-Stage Schizophrenia and Healthy Controls

  2022cites this paper
• Beyond antipsychotics: a twenty-first century update for preclinical development of schizophrenia therapeutics

  2022cites this paper
• Negative symptoms in First-Episode Schizophrenia related to morphometric alterations in orbitofrontal and superior temporal cortex: the OPTiMiSE study

  2022cites this paper
• Paradigm shift on the concept of schizophrenia that matches with both academic and clinical needs.

  2022cites this paper
• Investigating structural subdivisions of the anterior cingulate cortex in schizophrenia, with implications for treatment resistance and glutamatergic levels

  2022cites this paper
• Subcortical volume reduction and cortical thinning 3 months after switching to clozapine in treatment resistant schizophrenia

  2022cites this paper
• Dopamine Synthesis Capacity and GABA and Glutamate Levels Separate Antipsychotic-Naïve Patients With First-Episode Psychosis From Healthy Control Subjects in a Multimodal Prediction Model

  2022cites this paper
• Anterior cingulate glutamate metabolites as a predictor of antipsychotic response in first episode psychosis: data from the STRATA collaboration

  2022cites this paper
• A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia

  2022cites this paper
• Pharmacological and nonpharmacological augmentation treatments for clozapine-resistant schizophrenia: A systematic review and network meta-analysis with normalized entropy assessment.

  2022cites this paper
• Neurofunctional correlates of glutamate and GABA imbalance in psychosis: A systematic review.

  2022cites this paper
• Treatment Resistance: A Time-Based Approach for Early Identification in First Episode Psychosis

  2021cites this paper